Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | DRD1 | P21728 | 2/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.52 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD5 | P21918 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027352 | 0.94 | DRD2 (0.57) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL9293011 | 0.92 | MGLL (0.58) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL7470818 | 0.92 | MGLL (0.58) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL1383141 | 0.87 | DRD2 (0.63) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL31674607 | 0.87 | DRD2 (0.68) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL28368586 | 0.87 | DRD2 (0.68) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL11232474 | 0.87 | DRD2 (0.68) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL2323457 | 0.85 | DRD2 (0.65) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL8398287 | 0.85 | MGLL (0.68) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL21002079 | 0.85 | MGLL (0.68) | DRD2DRD1TAAR1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111836849-A | Process for producing fibers, films and moldings of polybenzazole polymer (P) | 巴斯夫欧洲公司 | 2020-10-27 | — | — | CN | disclosed |
| US-7183296-B2 | Anti-HIV pyrazole derivatives | ROCHE PALO ALTO LLC (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1341766-B1 | IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-20040192752-A1 | Anti-HIV pyrazole derivatives | DYMOCK BRIAN WILLIAM (GB) | 2004-09-30 | — | — | US | disclosed |
| US-6699887-B2 | ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A PYRRAZOLE SULFIDE OR ETHER COMPOUND TO TREAT THE HUMAN IMMUNODEFICIENCY VIRUS INFECTION | HOFFMANN-LA ROCHE INC. | 2004-03-02 | — | — | US | disclosed |
| EP-1341766-A1 | IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| EP-1326843-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | F. Hoffmann-La Roche AG (CH) | 2003-07-16 | — | — | EP | disclosed |
| US-6518293-B2 | Inhibitors of the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication. | HOFFMANN-LA ROCHE INC. | 2003-02-11 | — | — | US | disclosed |
| US-20030018197-A1 | Anti-HIV pyrazole derivatives | HOFFMANN-LA ROCHE INC. | 2003-01-23 | — | — | US | disclosed |
| US-20020107272-A1 | Anti-HIV imidazolone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-08 | — | — | US | disclosed |
| US-5008274-A | Carbostyril derivatives and salts thereof and pharmaceutical composition for inhibiting adhesion of thrombocytes | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-16 | — | — | US | disclosed |
| US-4766120-A | ANTIINFLAMMATORY AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1988-08-23 | — | — | US | disclosed |
| EP-0240015-A2 | Carbostyril derivatives, process for preparing them, pharmaceutical composition, and use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-07 | — | — | EP | disclosed |
| US-4663323-A | Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0078462-B1 | 1,2,4,6-THIATRIAZINE-1,1 DIOXIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-GROWTH AGENTS FOR UNWANTED PLANTS | BASF Aktiengesellschaft (DE) | 1986-01-15 | — | — | EP | disclosed |
| EP-0035046-B1 | NOVEL TETRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-02 | — | — | EP | disclosed |
| US-4540703-A | Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1985-09-10 | — | — | US | disclosed |
| US-4472191-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1984-09-18 | — | — | US | disclosed |
| EP-0078462-A1 | 1,2,4,6-Thiatriazine-1,1 dioxides, process for their preparation and their use as anti-growth agents for unwanted plants | BASF Aktiengesellschaft (DE) | 1983-05-11 | — | — | EP | disclosed |
| EP-0035046-A1 | Novel tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192752-A1 | Anti-HIV pyrazole derivatives | CYP51A1, TYMP, POLRMT | DRD2 3931/4885DRD1 3129/4885TAAR1 4789/4885 |
| US-20020107272-A1 | Anti-HIV imidazolone derivatives | EIF2AK2, IMPDH1, POLR2E | DRD2 3354/4885DRD1 2957/4885TAAR1 4853/4885 |
| US-20030018197-A1 | Anti-HIV pyrazole derivatives | CYP51A1, TYMP, POLRMT | DRD2 3931/4885DRD1 3129/4885TAAR1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.